Sarepta Therapeutics (NASDAQ:SRPT) Upgraded by Wolfe Research to “Outperform” Rating

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by investment analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a $27.00 price target on the biotechnology company’s stock. Wolfe Research’s price objective points to a potential upside of 33.60% from the stock’s current price.

SRPT has been the subject of several other research reports. Royal Bank Of Canada raised their price objective on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, June 29th. Wedbush increased their target price on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 26th. Zacks Research cut shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Nine research analysts have rated the stock with a Buy rating, ten have given a Hold rating and seven have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $24.91.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $20.21 on Thursday. The firm has a market cap of $2.13 billion, a PE ratio of -21.05, a price-to-earnings-growth ratio of 0.21 and a beta of 0.21. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. The stock has a 50-day moving average price of $17.80 and a 200-day moving average price of $19.29. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, beating the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The company had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.15 million. During the same quarter in the prior year, the company earned ($3.42) EPS. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, equities research analysts expect that Sarepta Therapeutics will post 3.95 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the business. Kestra Advisory Services LLC bought a new stake in Sarepta Therapeutics during the 4th quarter valued at $25,000. iSAM Funds UK Ltd acquired a new position in shares of Sarepta Therapeutics during the third quarter valued at about $25,000. Ancora Advisors LLC increased its position in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares in the last quarter. Allworth Financial LP increased its position in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 165.3% in the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 1,256 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.